1.
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
by Roviello, Giandomenico
Cancer letters, 2016, Vol.372 (2), p.187-191
2.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim result...
by Sequist, Lecia V
The lancet oncology, 2020-03, Vol.21 (3), p.373-386
3.
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
by Tan, Chee-Seng
Lung cancer (Amsterdam, Netherlands), 2016, Vol.93, p.59-68
4.
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
by Garofalo, Michela
Nature medicine, 2011-12-11, Vol.18 (1), p.74-82
5.
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
by Medina, Patrick J., PharmD, BCOP
Clinical therapeutics, 2008, Vol.30 (8), p.1426-1447
6.
Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
by Tong, Christy W.S
Cancer letters, 2017-10-01, Vol.405, p.100-110
7.
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
by Yamaguchi, Norihiro
Lung cancer (Amsterdam, Netherlands), 2013, Vol.83 (1), p.37-43
8.
Essential role for EGFR tyrosine kinase and ER stress in myocardial infarction in type 2 diabetes
by Mali, Vishal
Pflügers Archiv, 2017-12-29, Vol.470 (3), p.471-480
9.
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
by Park, S.J
Lung cancer (Amsterdam, Netherlands), 2012, Vol.77 (3), p.556-560
10.
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
by Liao, Bin-Chi
Lung cancer (Amsterdam, Netherlands), 2017-08, Vol.110, p.7-13
11.
Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome—positive acute lymphoblastic leukemia
by Steinberg, Michael, PharmD, BCOP
Clinical therapeutics, 2007, Vol.29 (11), p.2289-2308
12.
Real-world Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States
by Henk, Henry J., PhD
Clinical therapeutics, 2015, Vol.37 (1), p.124-133
13.
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia
by Breccia, Massimo
Cancer letters, 2014, Vol.347 (1), p.22-28
14.
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
by Sun, Jong-Mu
Lung cancer (Amsterdam, Netherlands), 2013, Vol.82 (2), p.294-298
15.
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials
by Li, Bob T
Lung cancer (Amsterdam, Netherlands), 2016, Vol.102, p.21-27
16.
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
by Kim, Min Hwan
Lung cancer (Amsterdam, Netherlands), 2014, Vol.84 (2), p.196-202
17.
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors
by Santoni, Matteo
Annals of surgical oncology, 2014-12-04, Vol.22 (6), p.2094-2100
18.
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
by Ou, Sai-Hong Ignatius
Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.61-64
19.
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials
by Petrelli, Fausto
Lung cancer (Amsterdam, Netherlands), 2012, Vol.78 (1), p.8-15
20.
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
by Zhao, Qiong
Lung cancer (Amsterdam, Netherlands), 2010, Vol.73 (2), p.195-202
